Cargando…

Effects of cyclophosphamide combined with prednisone on TNF-α expression in treatment of patients with interstitial lung disease

Effects of cyclophosphamide combined with prednisone on TNF-α expression in the treatment of patients with interstitial lung disease (ILD), and its clinical significance were investigated. A prospective analysis was performed on 198 patients with ILD in Jinan Central Hospital Affiliated to Shandong...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jun, Chen, Xiuling, Qu, Yunping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862246/ https://www.ncbi.nlm.nih.gov/pubmed/31777548 http://dx.doi.org/10.3892/etm.2019.8099

Ejemplares similares

Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide
por: Kikuchi, Taku, et al.
Publicado: (2017)

Cyclophosphamide/prednisone: Various infections: case report
Publicado: (2021)

Cyclophosphamide/methylprednisolone/prednisone: No improvement: case report
Publicado: (2022)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies
por: Laurencet, F M, et al.
Publicado: (1999)

Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature
por: Innabi, Ayoub, et al.
Publicado: (2021)

Complete remission of coronary vasculitis in Churg–Strauss Syndrome by prednisone and cyclophosphamide
por: Riksen, Niels P., et al.
Publicado: (2010)

Long Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease
por: Mittoo, S, et al.
Publicado: (2011)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
por: Johnston, Patrick B., et al.
Publicado: (2021)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020)

Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases
por: Nucera, Valeria, et al.
Publicado: (2021)

Interstitial lung disease due to anti-TNF use in the treatment of psoriasis()()
por: Turíbio, Débora Dorneles Cunha de Queiroz, et al.
Publicado: (2021)

Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
por: Cherukuri, Sundar V, et al.
Publicado: (2021)

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
por: Shi, Haotian, et al.
Publicado: (2023)

Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy
por: Matsukawa, Toshihiro, et al.
Publicado: (2018)

Cyclophosphamide/doxorubicin/prednisone: Prolonged COVID-19 viral shedding, neutropenia and thrombocytopenia: case report
Publicado: (2021)

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
por: van Keep, Marjolijn, et al.
Publicado: (2016)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

P773: CYCLOPHOSPHAMIDE COMBINED WITH PREDNISONE FOR CYCLOSPORINE-REFRACTORY/RELAPSED T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA ASSOCIATED PURE RED CELL APLASIA
por: Liu, Xiaoqing, et al.
Publicado: (2023)

Intravenous Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease: A Long Term Study
por: Simeón-Aznar, C.P, et al.
Publicado: (2008)

RESISTANCE OF LONG-LIVED LYMPHOCYTES AND PLASMA CELLS IN RAT LYMPH NODES TO TREATMENT WITH PREDNISONE, CYCLOPHOSPHAMIDE, 6-MERCAPTOPURINE, AND ACTINOMYCIN D
por: Miller, John J., et al.
Publicado: (1967)

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function
por: Thakar, Keyur, et al.
Publicado: (2014)

Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
por: Yin, Xietian, et al.
Publicado: (2023)

Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy
por: Lin, Qingqing, et al.
Publicado: (2023)

The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
por: Feng, Xiaomeng, et al.
Publicado: (2021)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Curative effect and safety of propranolol combined with prednisone in the treatment of infantile hemangiomas
por: Lou, Huanmin, et al.
Publicado: (2018)

Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics
por: van Gemert, Johanna P., et al.
Publicado: (2021)

Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
por: Kim, Jong Gwang, et al.
Publicado: (2004)

Eptacog-α/prednisone/rituximab: No response: case report
Publicado: (2021)

Treatment and Prognosis of Patients with Lung Cancer and Combined Interstitial Lung Disease
por: Mauclet, Charlotte, et al.
Publicado: (2023)

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
por: Saunders, Peter, et al.
Publicado: (2017)

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
por: Fraticelli, Paolo, et al.
Publicado: (2014)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
por: Steiner, R., et al.
Publicado: (2022)

The Efficacy of Cyclophosphamide Combined with Prednisone in Membranous Nephropathy Patients with Different Cytochrome P450 2B6 Gene Polymorphisms and Analysis of Factors Influencing the Efficacy
por: Zhang, Min, et al.
Publicado: (2022)

Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis
por: Li, Lian, et al.
Publicado: (2022)

Proliferation of Interstitial Cells in the Cyclophosphamide-Induced Cystitis and the Preventive Effect of Imatinib
por: Sancho, Maria, et al.
Publicado: (2017)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
por: Rak, Mariola B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ic383jq61druvdsubl0cri9rs3